新型预后模型(SCAD评分)预测胰腺癌立体定向体部放疗再照射后的总生存
该研究基于31例接受两程SBRT的胰腺癌患者,用Cox比例风险模型建立SCAD评分,并在11例验证队列中评估。多变量分析显示肿瘤分期(P=0.005)、BED10(P=0.006)和CA19-9反应(P=0.04)显著预测总生存;验证队列中评分<3分者总生存优于≥3分者(中位OS未达到 vs 15.9个月,P=0.032)。作者认为SCAD评分可能有助于识别从再照射SBRT中获益的个体。
要点
- SCAD评分由肿瘤分期、BED10和CA19-9反应构成,三者均与总生存显著相关。
- 验证队列中评分<3分者中位OS未达到,≥3分者为15.9个月(P=0.032)。
- 作者认为该评分可能有助于筛选从再照射SBRT中获益的胰腺癌患者。
核心结论
- SCAD评分可能具有识别从再照射SBRT中获益个体的潜力,并朝着更个性化医疗迈进一步。
研究设计与样本
- 基于31例接受两程SBRT的胰腺癌患者,采用Cox比例风险模型建立SCAD评分,并在另一11例验证队列中评估评分性能。
主要发现
- 训练队列第一次和第二次SBRT的中位BED10分别为59.5 Gy(48-85.5 Gy)和50.2 Gy(43.7-66.9 Gy),分5-8次。
- 验证队列第一次和第二次SBRT的中位BED10分别为59.5 Gy(52.5-66.9 Gy)和47.7 Gy(40.6-54.8 Gy),分5-8次。
- 训练队列和验证队列第一次与第二次SBRT的间隔分别为10.5个月(6.1-24.3个月)和12.8个月(6.5-29.1个月)。
- 多变量分析显示肿瘤分期(P=0.005)、BED10(P=0.006)和CA19-9反应(P=0.04)对总生存有显著预测作用,构成SCAD评分。
- 验证队列中评分<3分者总生存优于评分≥3分者(中位OS未达到 vs 15.9个月,P=0.032)。
关键数值与推荐
- SCAD评分由肿瘤分期、BED10和CA19-9反应三个因素构成。
- 验证队列中评分<3分者中位OS未达到,评分≥3分者中位OS为15.9个月(P=0.032)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a predictive model for stratification of patients with pancreatic cancer who may achieve survival benefits from re-irradiation with stereotactic body radiation therapy (SBRT). METHODS: The score was developed based on clinical predictors of OS in 31 patients receiving two courses of SBRT with Cox proportional hazards model. Results were then validated in another cohort with 11 participants to assess the performance of the score. RESULTS: In the training cohort, the median BED10 of the first and second SBRT was 59.5 Gy (48-85.5 Gy) and 50.2 Gy (43.7-66.9 Gy) in 5-8 fractions, while in the validation cohort, the median BED10 of the first and second SBRT was 59.5 Gy (52.5-66.9 Gy) and 47.7 Gy (40.6-54.8 Gy) in 5-8 fractions. The interval between the first and second SBRT of the training cohort and validation cohort was 10.5 months (6.1-24.3 months) and 12.8 months (6.5-29.1 months), respectively. Multivariable analysis showed that tumor stage (P = 0.005), BED10 (P = 0.006) and CA19-9 response (P = 0.04) were significantly predictive of overall survival, which formed SCAD score (named after the initials of factors). Patients with the score < 3 points had a superior OS compared with those with the score ≥ 3 points in the validation cohort (median OS has not been reached vs. 15.9 months, P = 0.032). CONCLUSIONS: The SCAD score may have the potential to identify individuals benefiting from re-SBRT and be a step toward more personalized medicine.
引用
- Zhu X, Li F, Ju X, et al. Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score). Radiother Oncol. 2018. PMID: 30217337. doi:10.1016/j.radonc.2018.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。